NCT06208137
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
StatusTerminated
PhaseNot applicable
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Insufficient execution and compliance Show 4 more changesShow less
- Eligibility criteria expanded, about 6 words
- Final enrollment: 150 participants (planned 456)
- Primary completion date changed from estimate of Oct 1, 2027 to Jan 1, 2026
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 1, 2024 to Feb 29, 2024
- Site details revised
Notable Enrollment target: 1000 to 456v2 Show 5 more changesShow less
- Start date: Feb 2024 to Apr 1, 2024
- Eligibility criteria expanded, about 1 word
- Primary completion date: Feb 2028 to Oct 1, 2027
- Study completion date: Jul 2028 to Apr 1, 2028
- Secondary endpoints: details revised at 3 of 3 entries
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Survival
Timeframe: 1.5 years after transplantation
Secondary (3)
Non-relapse mortality rate
Incidence of infections
Immune cell count
Arms and interventions
Intervention groupExperimental
Remind patients to test their immune status among 120-180 days post-transplantation. Physicians assessed the risk level of patients in the intervention group based on their immune status on days 91-180 using the CIRS.
Control groupNo intervention
Only remind patients to test their immune status among 120-180 days post-transplantation.
Behavioral: Health monitoring and regular return follow-up reminders
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China